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Abstract
Background: Clinical appearance and evolution of Canine Leishmaniosis (CL) are the consequence of complex
interactions between the parasite and the genetic and immunological backgrounds. We investigated the effect of
an immune-modulating diet in CL. Dogs were treated with anti- Leishmania pharmacological therapy combined
with standard diet (SD Group) or with the immune-modulating diet (IMMD Group). CD3+ CD4+ Foxp3+ Regulatory
T cells (Treg) and CD3+ CD4+ IFN-γ + T helper 1 (Th1) were analyzed by flow cytometry.
Results: All sick dogs showed low platelet number at diagnosis (T0). A platelet increase was observed after six
months (T6) SD Group, with still remaining in the normal range at twelve months (T12). IMMD Group showed an
increase in platelet number becoming similar to healthy dogs at T6 and T12. An increase of CD4/CD8 ratio was
revealed in SD Group after three months (T3), while at T6 and at T12 the values resembled to T0. The increase in
CD4/CD8 ratio at T3 was maintained at T6 and T12 in IMMD Group.
A reduction in the percentage of Treg of all sick dogs was observed at T0. A recovery of Treg percentage was
observed only at T3 in SD Group, while this effect disappeared at T6 and T12. In contrast, Treg percentage became
similar to healthy animals in IMDD Group at T3, T6 and T12. Sick dogs showed an increase of Th1 cells at T0 as
compared with healthy dogs. We observed the occurrence of a decrease of Th1 cells from T3 to T12 in SD Group,
although a trend of increase was observed at T6 and T12. At variance, IMMD Group dogs showed a progressive
decrease of Th1 cells, whose levels became similar to healthy controls at T6 and T12.
Conclusion: The immune-modulating diet appears to regulate the immune response in CL during the standard
pharmacological treatment. The presence of nutraceuticals in the diet correlates with the decrease of Th1 cells and
with the increase of Treg in sick dogs. Therefore, the administration of the specific dietary supplement improved
the clinical response to the standard treatment in a model of CL.
Keywords: Leishmaniosis, Pharmacological treatment, Nutraceuticals, Nutrition, Immune profile, Treg
* Correspondence: terrazza@unina.it
3Department of Translational Medical Sciences, University of Naples Federico
II, Via Pansini, 5, 80131 Naples, Italy
6Department of Science, University of Basilicata, Via Sauro, 85, 85100 Potenza,
Italy
Full list of author information is available at the end of the article
© 2015 Cortese et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Cortese et al. BMC Veterinary Research  (2015) 11:295 
DOI 10.1186/s12917-015-0610-7
Background
Canine Leishmaniosis (CL) is a zoonotic disease for
humans and dogs and is caused by the protozoan parasite
Leishmania (L.) infantum in the Mediterranean area [1].
Several clinical manifestations have been described in
CL [2, 3] and the clinical appearance and evolution of
Leishmaniosis appear to be the consequence of complex
interactions between the parasite and the genetic and
immunological profile of the host [1, 4]. CL is a non
self-limiting infection causing severe disease [1–3], but
is often manifested as sub clinical infection with the fea-
tures of a self-limiting disease [5, 6].
Peculiar immunological profiles characterize the two
opposite extremes of this clinical spectrum: the cell-
mediated immunity, mainly based on Interferon (IFN)-γ
secreting T helper (Th) 1 lymphocytes, and the anti-
Leishmania macrophage activity, which has been associ-
ated with self-limiting disease [7].
In contrast, occurrence of severe illness has been de-
scribed in presence of a marked humoral immune re-
sponse, accompanied by reduced or depressed cell
mediated immunity with mixed Th1 and Th2 cytokine
responses [1, 7]. Clinical signs of disease range from a
mild dermatitis and alopecia, associated with specific
cellular immunity [8], to a severe disease with renal
damage and glomerulonephritis [9]. L. infantum infected
dogs could remain clinically healthy for an indeter-
minate period of time or life along [10]. Such occur-
rence has been associated with the cellular Th1
immunity [1, 11–13].
Different treatment protocols and prognoses have been
suggested for the clinical stages of CL [11]. The combin-
ation of N-methylglucamine antimoniate with Allopurinol
is considered the gold standard therapy in CL [11, 14–16].
Clinical response ranges from poor to good, in depend-
ence on the overall initial clinic status of animals and on
its individual response to therapy [1–3, 8–11, 17–20].
The critical relevance of host-immune response in CL
outcome has been largely demonstrated [1, 11–13, 21].
A complex network of peripheral mechanisms, which
are co-evolved to prevent or dampen immune mediated
diseases, usually accounts for the activation, expansion
and recruitment of T lymphocyte effectors in the in-
fected animals. Regulatory systems include mechanisms
intrinsic to the antigen-dependent T cell activation as
well as the regulatory suppressor immune-populations,
mainly represented by Regulatory T cells (Treg) [22].
Notably, it is conceivable that Treg activity could
down-modulate the same inflammatory responses re-
quired for infection clearance [22]. During CL, such oc-
currence may exacerbate the risk that the unbridled
parasite growth could lead to a severe disease. However,
Treg recruitment is necessary to prevent the onset of se-
vere immune-mediated mechanisms in infected tissues,
particularly for the presence of autoimmune processes
highly frequent in CL [11, 23–27]. We previously sug-
gested that the increase of cytotoxic T lymphocytes and
of Th1 cells together is associated with a reduction of
the Treg characterize the CL dogs [28] In addition,
Leishmania-specific Treg cells are observed to sites of
infection and were described to be dependent on
parasite persistence [29]. Notably, the equilibrium be-
tween Treg cells and effector lymphocytes appears to
control the efficiency of immune responses and dis-
ease reactivation [30].
Moreover, it is worth noting that an unbalanced diet
and malnutrition could represent primary causes of im-
mune suppression and have been demonstrated to be a
major risk factor for the development of visceral Leishma-
niosis in humans or animal models [31–34]. Furthermore,
the pathways that control immune cell function and me-
tabolism are intimately linked and this relationship might
intriguingly provide new strategies to modulate immune
functions in several infectious diseases [35, 36].
It is of some relevance that the role of some biological
principles - mainly derived from plants and usually re-
ferred as nutraceuticals - appears to be of some rele-
vance in modulating the immune system homeostasis
[37] as well as their use is of efficacy in dogs [38–41].
In this regard, Cucumis melo, Aloe vera, Punica grana-
tum, Piper nigrum, Camellia sinensis, Ascophyllum
nodosum, Grifola frondosa, Glycine max, Echinacea pur-
purea, Poligonum spp, Carica papaya and Curcuma
longa have been described to mediate several immune-
modulating effects [42–56]. Anti-oxidant properties have
been described for Cucumis melo, Carica papaya and
Curcuma longa, astaxanthin from Haematococcus plu-
vialis as well as for poly-unsaturated fatty acids derived
from fish oil. The extracts of Piper nigrum, Camellia
sinensis, Grifola frondosa and Glicine max have been as-
sociated with the modulation of inflammatory pathways
[57–61]. Punicalagin, the most important active sub-
stance contained in the fruit of Punica granatum, exerts
an immune suppressant activity [47]. Resveratrol, ex-
tracted from Poligonum cuspidatum, induces a signifi-
cant reduction in the generation of reactive-oxygen
species and can suppress plasma concentrations of
pro inflammatory factors like Tumor Necrosis Factor
(TNF)-α, Interleukin (IL)-6, and C-reactive protein in
humans [62].
In the present study a specific commercial nutraceut-
ical pet food was used as potential immune-modulating
diet (IMMD) containing anti-inflammatory and anti-
oxidant nutrients and associated with standard anti-
Leishmania pharmacological treatment in 20 dogs
naturally infected by L. infantum (IMMD Group). The
nutraceutical pet food consisted in a mixed formula of
Ascophyllum nodosum, Cucumis melo, Carica papaya,
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Aloe vera, Astaxanthin from Haematococcus pluvialis,
Curcuma longa, Camellia sinensis, Punica granatum,
Piper nigrum, Poligonum spp, Echinacea purpurea,
Grifola frondosa, Glycine max, Omega 3 and Omega 6
un-saturated fatty acids from fish oil. As control diet we
used a standard diet (SD) based on a commercial pet
food without nutraceuticals in 20 CL affected dogs (SD
Group).
Since the dogs of SD Groups were enrolled consider-
ing the same criteria for the inclusion of those of IMMD
Group (see also “Animals and study design” paragraph),
the dogs of both groups strongly matched for the start-
ing clinical features except for the type of diet adminis-
trated during the study. This approach consents to
properly evaluate the potential effects of the immune-
modulating diet in a cohort of dogs affected by CL
(IMMD Group) in comparison with CL dogs fed with a
standard diet (SD Group). Therefore, we evaluated T cell
subsets, peripheral blood Treg and Th1 cells at diagnosis
and along one-year follow-up in the two groups of sick
dogs. To ascertain the degree of changing induced by
immune-modulating diet, the results were compared
also with the same type of immune-profiles measured in
a cohort of 20 sex/age paired healthy dogs.
Methods
Ethic statement
This study has been reviewed by Ethical Animal Care
and Use Committee of the University of Naples Federico
II and received formal Institutional approval (Centro
Servizi Veterinari, Università di Napoli FEDERICO II,
prot. N. 2015/0071388) in accordance with local and na-
tional law, regulations and guidelines. Moreover, the en-
rolled dogs simply changed the type of food by using
commercial products. So, there is no real implementa-
tion of an experimental practice to test the effects of a
new food, but a mere evaluation of the clinical and func-
tional response of a commercial diet at potential
immune-modulating effect in CL. This study avoided
discomfort to the animals by the use of proper clinical
management. Blood sample collection was cruelty free,
without any bloody operation and did not provide for
any segregation, even partial, of the animal. In this
regards, the study was performed only on household
dogs. All enrolled sick animals regularly received the
standard therapy for CL.
The diets
Two groups of dogs (see “Animals and study design”
paragraph) were fed two commercial dry pet foods
(IMMD and SD) all along the study. An additional
group, formed by healthy dogs and analyzed once a time
in the trial (see “Animals and study design” paragraph),
was fed with standard diets based on the commercial
foods to which the animals were already used at the time
of the analysis.
All the diets completely fulfill the recommendations
for protein, carbohydrate and fat in order to obtain a
complete food for a daily ration in dog (as reported in
Nutritional Guidelines for complete and complementary
pet food for cats and dogs by The European Pet Food
Industry Federation). All the foods are commercial and
in the form of kibbles industrially produced with extru-
sion technique.
The IMMD and SD foods, used all along the trial, re-
ported similar analytical composition in nutrients (24 %
of crude protein, 12 % of crude oils and fats, 3.7 %, of
crude fiber 5 % of crude ash, 9 % of moisture) and, as a
consequence, similar Metabolized Energy (ME) of
3.477 kcal/kg corresponding to 14.6 MJ/kg. The IMMD
was composed by two mixed components: kibbles, in-
cluded in the ideal percentage of 93-94 % in weight, and
cold-pressed tablets at the 6–7 % in weight of complete
food (European patent n. EP 2526781). Overall nutrient
profile of the product was obtained by the sum of a first
nutrient profile of the kibbles, for feeding purpose, and a
second nutrient profile of the tablets for both nutrient
and therapeutic purposes. Tablets were composed by
60–80 % of protein hydrolyzed (fish and vegetable ones),
20–40 % of minerals used as glidants and were added by
therapeutical substances (Ascophyllum nodosum, Cucu-
mis melo, Carica papaya, Aloe vera, Astaxanthin from
Haematococcus pluvialis, Curcuma longa, Camellia
sinensis, Punica granatum, Piper nigrum, Poligonum spp,
Echinacea purpurea, Grifola frondosa, Glycine max,
Omega 3 and Omega 6 un-saturated fatty acids from
fish, as 1.60 and 1.25 % of oil respectively.
The dry pet food used as SD did not contain the
above-mentioned active substances.
The IMMD and SD dietary administration were care-
fully adjusted during the trial to provide similar caloric
animal food intake and to satisfy the nutritional require-
ment of adult dogs (Table 1). In this regard, the food has
been administered twice a day by dog’s owners, accord-
ing to the specific requirements for the nutrient amount.
Owners were instructed to strictly follow the daily diet-
ary tables formulated by veterinarians, according with
Manufacturer’s Instructions, as indicated in Table 1.
To guarantee the maintenance energy requirement,
food dosage was established using a daily dietary
Table 1 Daily table recommendation for diet
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administration (Table 1) based on the equation 130 kcal
ME/kg of Body Weight0.75 as recommended by the Na-
tional Research Council Committee on Animal Nutri-
tion, USA. The coefficient used referred to a moderate
activity.
In addition, veterinarians have weekly provided and
measured the required amount of food to ensure the
proper administration to the dogs all along the trial. The
IMMD and SD commercial products completely respect
the nutritional guidelines established by European Pet
Food Industry Federation to provide all nutrients neces-
sary for a canine diet.
Animals and study design
Forty dogs naturally infected by L. infantum (20 males
and 20 females, 5–9 years old) from the Campania re-
gion (South Italy), which is a CL endemic area, were en-
rolled with the owner consent. Ten dogs were pure
breed (4 German Shepherds, 4 Rottweilers and 2 Labra-
dor Retrievers), while 30 were mongrels (15 females and
15 males, between 20 and 35 kg in weight). The study
was performed on household dogs in order to avoid any
possible interference dependent on usual environment
changing. The pet food was daily administered to the
dogs by the owners following the daily dietary tables (see
“The diets” paragraph and Table 1). The dogs were
under the biweekly supervision of the veterinaries (De-
partment of Veterinary Medicine and Animal Produc-
tions, Division of Internal Medicine, University of
Naples Federico II, Italy) in order to perform a complete
clinical evaluation potentially able to reveal any illness
state or nutritional deficiency. The recommendations of
the ARRIVE guidelines in animal research were also
consulted and considered [63].
Animals were allocated to two groups during the
12 months of the trial. SD Group was composed of 20
dogs treated with meglumine antimoniate (50 mg/kg,
subcutaneous, twice daily, for 1 month), allopurinol
(10 mg/kg, oral, twice daily, for 6 months) and fed with
standard diet. IMMD Group included 20 dogs subjected
to the same therapeutic treatment combined with the
administration of a diet with potential immune-
modulating activity (see also “The diets” paragraph). An-
imals were equally distributed for breed, sex, weight and
clinical signs in the two groups. All the dogs from
IMMD and SD Groups fully adapted of new diets. Im-
mune profile evaluation was performed at diagnosis (T0)
and after three (T3), six (T6) and twelve (T12) months
of trial in all the animals. The full blood count, total pro-
teins, albumin/globulin ratio, urea and creatinine value
determinations and immune profile analysis were evalu-
ated at T0, T3, T6 and T12.
The additional control of 20 healthy dogs (12 males, 8
females, 5–7 years old) was analyzed for the same
parameters once a time at the beginning of the trial or,
in few cases, in the first 15–20 days from the starting
evaluation. In this regard, the latter group (Healthy
Dogs) provided an useful range of normality for T cell
subsets, Treg and Th1 cells in our trial. Indeed, the im-
mune profile evaluations of healthy dogs were used to
obtain the control means ± SD for each parameters
(platelet count, CD4/CD8 ratio, Treg and INF-γ mea-
surements) to be compared with CL infected dogs of
IMMD and SD Groups.
In addition, both indirect fluorescence antibody test
(IFAT) and sternal bone marrow aspirate for Leishmania
DNA detection by n-PCR were performed at T0 and
T12 in IMMD and SD groups and at T0 in healthy dog
control (see also “Serological and molecular assays”
paragraph).
Clinical evaluation of dogs
History and clinical examination were performed with
the accuracy of guideline criteria for CL diagnosis and
classified according to Solano-Gallego et al. [11].
According to AAHA Nutritional Assessment Guide-
lines for Dogs and Cats, animals were periodically re-
examined, for exclusion of signs of food intolerance or
allergies related to food or to the enviroment [64]. Thus,
pet owners were instructed to evaluate their pets for
food intake and appetite, body weight, gastrointestinal
signs (feces consistency and entity, vomiting), cutaneous
signs (pruritus, dermatitis, poor skin or hair coat), over-
all appearance and activity. The involved veterinarians
supervised all these aspects during the bi-weekly
inspection.
No dog received a specific treatment for CL before the
enrolment. Criteria for inclusion in this study were the
occurrence of clinical signs compatible with Leishmanio-
sis (weight loss, lethargy, pale mucous membranes, per-
ipheral lymphadenopathy, spleen enlargement, skin
lesions, ulcers, ocular signs). Clinical pathological
signs including anemia (hematocrit value < 37 %),
thrombocytopenia (platelets count < 200 × 103/μL),
increase of total proteins (>7,7 g/dL), hyperglobuline-
mia (albumin/globulin ratio < 0.6), and increase of
urea (>50 mg/dL) and creatinine (>1.5 mg/dL) were
evaluated. Acute onset of possible arthropod-borne
co-infections (such as ehrlichiosis, anaplasmosis or
babesiosis) was evaluated and ruled-out all along the
study (see also “Diagnostic procedure” paragraph).
Dogs were monitored for clinical signs correlated to
other illnesses potentially occurring during the trial.
Clinical recovery was evaluated at T3, T6 and T12
and was based on the reduction/disappearance of
clinical signs listed in the inclusion criteria.
Healthy dogs were enrolled on inclusion criteria that
considered the good state of health and the absence of
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signs related to infectious or metabolic diseases. Further-
more, these dogs were evaluated for the absence of sero-
logical indices of infectious diseases (see “Serological
and molecular assays” paragraph). History of these dogs
revealed that they had not received, in at least the
4 weeks before, any drug therapy can alter the results of
the analysis.
None of the dogs belonging to all groups of the study
showed signs of food intolerance or allergies related to
food or to the enviroment.
At the beginning of the study (T0) and during the
follow-up (T3, T6 and T12, for IMMD and SD Groups),
the dogs were evaluated for their weight by five-point
body condition score (BCS) [65]. Enrolled dogs were of
medium body weight of 27 + 2 kg while the BCS, which
assesses the nutritional status, ranged from 2.75 to 2.90.
All dogs of the three groups received, as usual, the
prophylaxis against infestations by fleas, ticks and mos-
quitoes by using a monthly local treatment spot-on of
specific commercial product. At the beginning of the
trial, the dogs were also dewormed with specific com-
mercial product and the treatment was repeated every
three months for each dog.
Blood sample collection
Peripheral blood was collected from the jugular vein into
tubes containing ethylene EDTA to perform both the
hematological profile and the experimental approach
(see also “Diagnostic procedure” paragraph). A complete
cell blood count was performed in each sample within
30 min from the collection by a semi-automatic cell
counter (Genius S; SEAC Radom Group, Florence, Italy).
May-Grünwald-Giemsa-stained blood smears were eval-
uated for additional confirmation of thrombocytopenia
or evidence of platelet clumping. All samples were main-
tained at room temperature up to 5–6 h prior to pro-
cessing. In addition, serum aliquots were obtained from
the dogs to perform the biochemical profile and sero-
logical examination.
The collection of biological samples was practiced in
accordance with the national guidelines for animal wel-
fare, only after owner informed consent and on the basis
of the received ethical approval (see Ethic Statement
paragraph).
Serological and molecular assays
Detection of anti-Leishmania IgG antibodies was per-
formed by an in-house IFAT assay using L. infantum
promastigotes (WHO reference strain MHOM/TN/
1980/IPT-1) as antigen and following the protocol rec-
ommended by the Office International des Epizooties
[66]. The cut-off dilution was set 1:160. A sternal bone
marrow aspirate for Leishmania DNA detection by
nested polymerase chain reaction (n-PCR) was
performed. Briefly, the first amplification was carried out
in a 50 μl reaction containing 10 μl DNA and 40 μl PCR
Master Mix (Promega) with 50 pmol of the
kinetoplastid-specific primers R221 and R332 of the
small-subunit rRNA gene [67]. For the second amplifica-
tion, 3 μl of the first PCR product were added to 47 μl
of PCR Master Mix (Promega) containing 50 pmol of
the Leishmania-specific primers R223 and R333 of the
same gene [67].
IFAT for E. canis was performed using E. canis anti-
gen in DH82 cells with a cut-off titer of 1:80. For the
E. canis n-PCR assay, DNA was extracted from bone
marrow aspirate. Briefly, the first PCR was performed
in a 25 μl reaction containing 5 μl of DNA template
with 12.5 pmol of primer set of universal fD1 and
Ehrlichia genus-specific EHR16SR [68]. For the sec-
ond amplification, 5 μl of the first PCR product were
added to 20 μl of PCR Master Mix (Promega) con-
taining 12.5 pmol of the Ehrlichia-specific primers
CANIS and GA1UR of the same gene [68]. The amp-
lification products were analyzed by 1.5 % agarose gel
and visualized under UV light.
Diagnostic procedure
Diagnosis of CL was always confirmed by IFAT and by
PCR. Animals with clinical and/or clinical pathological
signs attributable to CL, anti-Leishmania antibody titers
(≥1:160) and positive molecular diagnosis, were included
in the study as infected animals (IMMD Group and SD
Group). Animals with the absence of clinical signs on
physical examination, showing negative IFAT (≤1: 80)
and PCR, were considered non-infected and included in
the healthy dog control group. Occurrence of infectious
and parasitic diseases other than CL was excluded in all
dogs. In particular, no evidence of Ehrlichia canis, Ana-
plasma phagocytophilum morulae, Babesia canis tropho-
zoites and microfilariae was observed in peripheral
blood smears. Ehrlichiosis was also excluded using IFAT
and n-PCR (see also “Serological and molecular assays”
paragraph). Finally, Dirofilaria immitis infection was
ruled out using the Snap Canine Combo Heartworm
Antigen Antibody Test (IDEXX).
In addition, the intestinal parasitic infections were ex-
cluded in all dogs, before the enrolment. Feces were col-
lected, stored at +4 °C and examined within 48 h.
Macroscopic examination was firstly performed for the
detection of proglottids of cestodes. Subsequently, each
fecal sample was divided into two aliquots. In order to
detect common parasite eggs and oocysts, one aliquot
was subjected to microscopic analysis by centrifugation-
flotation technique with sucrose and sodium nitrate so-
lution (specific gravity: 1360). The second aliquot was
used to detect Giardia cysts using the SNAP Giardia
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Test Kit (Idexx Laboratories). All samples tested were
negative for internal parasites in all the enrolled dogs.
Monoclonal antibodies, immunofluorescence, flow
cytometry and cell culture
Peripheral blood was employed to evaluate the level of
CD3 + CD4+, CD3 + CD8+ T cells and CD3 + CD4 +
Foxp3+ Treg cells [22] by immune-fluorescence tech-
nique and flow cytometry analysis, as previously de-
scribed [60]. FITC, Phycoerythrin (PE), Cy-chrome and
Allophycocyanin (APC) labeled monoclonal antibodies
(mAbs) against dog CD3 (Clone CA17.2A12), CD4
(Clone YKIX302.9), CD8 (Clone YCATE55.9), CD45
(clone CA12.10C12), IFN-γ (Clone CC302), IL-4 (Clone
CC303) and isotype-matched controls were purchased
from Serotec Ltd (London, UK). Intracellular detection
of Foxp3 was performed using a cross-reactive murine
FoxP3 antibody (Clone FJK-16 s, eBioscience, San Diego,
CA) and the permeabilization buffers provided by the
detection Kit (FoxP3 Staining Set, eBioscience), as de-
scribed [60, 61]. The detection of Treg was based on the
CD3+ CD4+ and Foxp3 staining FACS strategy, as de-
scribed [28, 69]. CD8+ and CD4+ T cell subsets were
always identified by a combination of canine specific
anti-CD3 together with anti-CD4 or anti-CD8 mAbs. To
analyze the production of IFN-γ, purified PBMC were
cultured overnight in presence of PMA and Ionomycin
(Sigma-Aldrich, St. Louis, MO). This approach has been
widely indicated for the study of cytokine profile in hu-
man and animal models [70, 71]. Intracellular staining
with the mAbs recognizing dog IFN-γ or isotype-
matched controls (Serotec) was performed by a fixing/
permeabilization kit (Caltag, Burlingame, CA). To avoid
extra cellular cytokine export, the cell cultures were in-
cubated in the presence of 5 μg/ml of Brefeldin-A
(Sigma-Aldrich, St. Louis, MO), as described [62].
Cells were cultured in RPMI 1640 (Biochrom K.G.,
Berlin, Germany) supplemented with 5 % heat inacti-
vated fetal bovine serum and 2 mM glutamine (Bio-
chrom) at 37 °C in 5 % CO2/95 % air. All phenotypes
referred to flow cytometry analysis of the lymphocyte
population gated by using Forward Scatter (FSC) and
Side Scatter (SSC) parameters. Flow cytometry and data
analysis were performed by using a two laser equipped
FACScalibur apparatus and the CellQuest analysis soft-
ware (Becton Dickinson, Mountain View, CA).
Statistical analysis
The statistical analysis was performed by the one way
Analysis of Variance (ANOVA) with the post-test correc-
tions according with Tukey-Kramer Test for Multiple
Comparisons using GraphPad Prism Software (Graph-
Pad Prism Inc, San Diego, CA, USA). Results were con-
sidered significant at p < 0.05.
Results
Clinical evaluation
Enrolled sick dogs were symptomatic. Clinical signs were
lymphadenopathy in 23 dogs of 40 (63 %), dermatitis in
13 dogs of 40 (33 %), alopecia in 10 dogs of 40 (25 %)
and splenomegaly in 20 dogs of 40 (50 %). A progressive
improvement of clinical conditions was evident in sick
dogs along the 12 months of follow-up. No significant
increment in dog body weight and in BCS was detected
at T3, T6 and T12 when compared to T0, regardless to
diet. PCR detection of the parasite DNA remained stead-
ily positive in all sick dogs during the study. None dog
evidenced allergies or food-intolerances during the trial.
No enrolled dog died during the trial.
The clinical recovery was evaluated considering the
disappearance of clinical signs at the end of the trial an
only basing on an on-site clinical observation. Therefore,
a statistical analysis was not performed for the clinical
recovery. Nevertheless, it could be of some relevance
that the disappearance of clinical signs was observed in
10 of 20 dogs (50 %) of the SD Group and in 13 of 20
dogs (65 %) of the IMMD Group.
In addition, all sick dogs showed a significant decrease
of platelet number at diagnosis (T0) in comparison with
healthy dogs (Fig. 1). This alteration completely disap-
peared at T12, regardless the group assignment. A
strong increase of platelets in SD Group dogs was ob-
served at T6, with a slight decrease at T12 but still
remaining in the normal range, since it was not statisti-
cally significant if compared with healthy dog controls.
IMMD Group dogs showed a significant increase in
platelet number becoming similar to healthy controls at
T6 and T12.
Comparative analysis of biochemical and hematological
parameters between SD Group and IMMD Group dogs
was performed at diagnosis (T0) and at T3, T6 and at
T12. Increase in the total protein amount and globulin
was observed in sick dogs. A/G ratio analysis showed no
significant changes in CL dogs, regardless the group as-
signment (not shown). Albumin levels and creatinine
values remained within the normal limits in all dogs dur-
ing the study.
Intriguingly, hemoglobin evaluation showed a mean
increase of more than 1.5 g/L in all CL dogs at T6 and
T12, regardless the group assignment as compared with
the T0 values (not shown).
No significant difference was observed along the
follow-up in the number of white blood cells in the CL
dogs, regardless the group assignment (data not shown).
Immune phenotype analysis
We analyzed CD4/CD8 ratio in dogs along the 12-
months of follow-up. As indicated in Fig. 2, we con-
firmed the significant decrease of CD4/CD8 ratio at T0
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in CL dogs when compared to healthy dogs, as by us
already described [60]. The observed increase of CD8+
T cells explains the decrease of CD4/CD8 ratio. This al-
teration remained substantially unmodified along the fol-
low up in both SD and IMMD Groups. Indeed, sick
dogs maintained a significant reduction of CD4/CD8 ra-
tio in comparison to control animals at all the time
points.
Moreover, when the analysis specifically focused on
CD4/CD8 ratio in the SD Group and IMMD Group, sig-
nificant differences between the groups were observed
along the follow-up. As shown, an increase of CD4/CD8
ratio was revealed in SD Group at T3 (0.81 ± 0.09; p <
0.001), while at T6 (0.58 ± 0.08) and at T12 (0.31 ± 0.02)
the values substantially resembled to those observed at
T0 (0.43 ± 0.05). At variance, the trend of increase in
CD4/CD8 ratio at T3 (0.73 ± 0.08 versus 0.46 ± 0.04) was
maintained at T6 (0.71 ± 0.08) and T12 (0.74 ± 0.09) in
IMMD Group. Notably, these values remained steadily
and significantly lower than in healthy dogs (Fig. 2). As
shown in Fig. 3, a significant reduction in the percentage
of Treg of all sick dogs was observed at T0. This result
confirms our previous observation on Treg levels in CL
[28]. A slight recovery of Treg percentage was observed
only at T3 in SD Group, while this effect disappeared at
T6 and T12. In contrast, it is worth noting that percent-
age of Treg became similar to healthy animals in IMDD
Group at T3, T6 and T12 (Fig. 3). Indeed, the differences
between the Treg percentages between healthy and
IMMD Group dogs substantially disappeared.
This result strongly suggests that the occurrence of a
quite stable recovery of Treg was correlated to the
immune-modulating diet administration.
In addition, anti-Leishmania treatment alone was un-
able to modify Treg level in CL. At variance, the com-
bination of drug with the potential immune-modulating
diet seems to be associated with a significant increase of
Treg population that reaches normal values in IMMD
Group.
Moreover, we asked if anti-Leishmania therapy alone
and/or associated with diet modification could affect
Th1 activity in CL. As shown in Fig. 4, sick dogs showed
a significant increase of Th1 cells at T0 as compared
with healthy dogs, regardless the group assignment. This
result is in accordance with our previous data on CL
[28]. The comparative analysis of sick dogs with healthy
controls revealed the occurrence of a significant de-
crease of Th1 cells from T3 to T12 in SD Group, al-
though a trend of increase was observed at T6 and T12.
At variance, IMMD Group dogs showed a progressive
decrease of Th1 cells, whose levels became similar to
healthy controls at T6 and T12.
Fig. 1 Analysis of platelet number. Values indicate the platelet
number in healthy dogs, in sick dogs at T0, T3, T6 and T12 in SD
Group (pharmacological treatment alone) and IMMD Group
(pharmacological treatment and immune-modulating diet), as
indicated. The column of Healthy Dogs refers to the means ± SD
values of normal range (see material and methods) of platelet count.
Results were considered significant at p < 0.05
Fig. 2 The CD4/CD8 ratio reduction is observed in CL sick dogs,
regardless the diet. Values indicate the CD4/CD8 ratio observed in
healthy dogs, in sick dogs at T0, T3, T6 and T12 in SD Group
(pharmacological treatment alone) and IMMD Group
(pharmacological treatment and immune-modulating diet), as indi-
cated. The column of Healthy Dogs refers to the means ± SD values
of normal range (see material and methods) of CD4/CD8 ratio in
healthy controls. Results were considered significant at p < 0.05
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Discussion
We analyzed the peripheral lymphocyte subsets, in
particular the Treg and Th1 cells, in 20 CL dogs
treated with standard anti-Leishmania pharmaco-
logical therapy combined to standard diet (SD Group)
and in 20 CL dogs treated with anti-Leishmania ther-
apy and the immune-modulating diet (IMMD Group).
The dogs of two groups were enrolled considering
the same inclusion criteria so that they strongly
matched for the starting clinical features except for
the type of diet administrated during the study. The
trial was performed on household dogs in order to
avoid any possible interference dependent on usual
environment changing and pet food was daily admin-
istered to the dogs by the owners following the daily
dietary tables (Table 1). The two diets provided simi-
lar caloric animal food intake and satisfied the nutri-
tional requirement of adult dogs.
Therefore, it is highly conceivable that the only notice-
able difference between the two diets is the presence of
nutraceuticals in the pet food administered to IMMD
Group dogs.
In light of this, our study suggested that a diet supple-
mented with Ascophyllum nodosum, Cucumis melo, Car-
ica papaya, Aloe vera, Astaxanthin from Haematococcus
pluvialis, Curcuma longa, Camellia sinensis, Punica
granatum, Piper nigrum, Poligonum spp, Echinacea pur-
purea, Grifola frondosa, Glycine max, Omega 3 and
Omega 6 un-saturated fatty acids from fish oil induced
an intriguing immune-modulation in CL dogs undergo-
ing 12 months of treatment with standard pharmaco-
logical therapy (IMMD Group).
In particular, we observed that the significant reduc-
tion of Treg subset, frequently associated with chronic
CL [28], was significantly restored by an immune-
modulating diet administration if compared to SD
Group dogs and when considering the “normal value”
(see Animals and study design paragraph) obtained by
Treg measurements in healthy dog controls. Such modi-
fication was maintained in a one-year follow-up. Not-
ably, IMMD Group dogs also showed a progressive and
significant decrease of Th1 cells, whose levels became
similar to healthy dogs at T6 and T12.
Fig. 3 The combination of the pharmacological treatment with an immune-modulating diet restores Treg percentage and count in sick dogs.
Panel A and B show the percentage and count (x10−6/L), respectively, of Foxp3 + CD4 + CD3+ (Treg) cells in healthy dogs, in sick dogs at T0, T3,
T6 and T12 in SD Group (pharmacological treatment alone) and IMMD Group (pharmacological treatment and immune-modulating diet), as
indicated. The column of Healthy Dogs refers to the means ± SD values of normal range (see material and methods) of Treg measurements in
healthy controls. Results were considered significant at p < 0.05
Fig. 4 Association of the pharmacological treatment with an
immune-modulating diet modulates the presence of IFN-γ+ IL−4-
CD3+ T lymphocytes (Th1) in sick dogs. Values indicated the
percentage of Th1 lymphocytes in healthy dogs, in sick dogs at T0,
T3, T6 and T12 in SD Group (pharmacological treatment alone) and
IMMD Group (pharmacological treatment and immune-modulating
diet), as indicated. The column of Healthy Dogs refers to the means
± SD values of normal range (see material and methods) of Th1
measurement in healthy controls. Results were considered significant
at p < 0.05
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Therefore, anti-Leishmania treatment combined
with specific nutraceutical diet, supplemented by nu-
trients selected for their potential immune-modulating
properties and rich in essential fatty acids, was associ-
ated with significant changes in immune profile of
sick dogs.
In this regard, it is of note that the nutraceuticals
used in this study were previously suggested as anti-
oxidants and immune-modulating substances to reach
the physiological status in several models of disease
in human [43, 62] and animals [49, 51, 54, 55, 61].
The effect of nutraceutical diet appeared to be specific
for Treg and Th1 lymphocytes, since other type of T
cells were substantially unaffected. Indeed, CL pharma-
cological treatment alone or in the presence of specific
immune-modulating nutrient supplementation did not
alter the CD4/CD8 ratio and did not affect the increase
in CD8+ T cell effectors in sick dogs along the follow-
up. Notably, the absence of effect on such T cell effectors
appears to be a favorable effect. Indeed, it is conceivable
that the maintenance of a high percentage of T cytotoxic
effectors could foster an effective immune response
against the parasite and it is mainly correlated to the
persistence of this chronic infection in the animals.
Moreover, the increase in Treg percentage could have a
role in reducing the immune-mediated damages to the
tissues frequently associated with CL. The decrease in
Th1 inflammatory response may sustain this hypothesis.
In this regard, both the clinical outcome of the
disease and the occurrence of immune-pathological
complications have been largely associated with the
anti-Leishmania immune response orchestration: i.e.
murine cutaneous Leishmaniosis model demonstrated
that Th1 and Th2 responses are in counter-regulatory
dependence [7].
It is of note that the pharmacological-treated dogs fed
with IMMD dietary regimen recovered their condition,
only basing on clinical observation, in a higher percent-
age if compared with those animals maintained with
standard diet (65 % vs. 50 %) at the end of the study. In
addition, the dogs treated with the combination of
standard therapy and the IMMD showed a significant in-
crease in platelet number along the study.
Conclusions
Our data evidenced as the pharmacological treatment
alone was unable to induce long lasting changes in pro-
inflammatory response and to modulate Treg in sick
dogs, while the combination with immune-modulating
diet was associated with a significant restoration of Treg
level and with the decrease in Th1 inflammatory
response.
Despite the effects on Treg and Th1 cells do not cor-
relate with fully changes in clinical outcome of infection,
it is of some relevance that the increase of Treg and the
modulation of Th1 inflammatory response could have a
role in reducing the immune-pathological injury result-
ing from CL disease.
In this context, the possibility that the occurrence of a
mild inflammatory context determined by increased Treg
level could ameliorate immune-mediated pathological ef-
fects, as the immune-mediated thrombocytopenia [28],
appears to be of some relevance.
Although further investigations are certainly needed
on the molecular mechanisms of these findings, to the
best of our knowledge this research represents one of
the few in vivo studies on the diet effects in modulating
the immune responses during infectious disease. This
study could open an interesting scenario on the role of
diet in modulating the immune response and to design
novel combined treatment against infectious disease for
dogs and, in perspective, for humans.
Study limitations
Notably, this research has some study limitations:
– the absence of control groups of dogs fed with other
anti-oxidant diet, able to verify the immune-
modulating properties of other extracts of plants
different from those employed in the present
research, represents the main relevant limitation;
– The use of a specific breed of dog, instead of a
mixed group of race, could highlight peculiarity in
disease susceptibility and in diet effects that may be
been unobserved in the use of a heterogeneous
group. At the same time, the here used
heterogeneous cohort of dogs could have the merit
to reveal general effects not segregated on race
specificity;
– Skin biopsy has been not performed to ascertain the
relevance for the parasitic spread in skin;
– Fecal examination has been not performed during
trial to rule out any possible interference of worms
in some dogs.
– None blinded study was conducted. Dog owners,
veterinarians and researchers involved in the study
were aware of the type of diet administered.
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